Enterobacteriaceae infections in Saudi Arabia
A regression analysis
Keywords:
Carbapenems, Enterobacteriaceae Infections, Mortality, Multiple Drug Resistance, Risk, TreatmentAbstract
Background: Carbapenem-resistant Enterobacteriaceae (CRE) are multidrug-resistant microorganisms. Infections caused by these microorganisms have limited treatment options, frequently leading to high mortality rates. Objective: This study aimed to identify the microbiological and clinical characteristics of CRE infections among hospitalized patients in a university hospital, and included treatment regimens, duration, infection-related mortality, and risk factors associated with death. Methods: the study analyzed the consecutive CRE infections in patients admitted to King Abdulaziz University Hospital (Jeddah, Saudi Arabia) between January 2014 and December 2016. Patients’ records for CRE infections at any sterile site during the study period were reviewed to analyze patient demographics, CRE risk factors, comorbidities, site of infection, antibiotic treatment, and septic shock. Therapeutic regimens including monotherapies, combination therapies, as well as different durations of treatment were also reviewed. The clinical outcome in this study was 30-day mortality. Statistical analyses were conducted by IBM© SPSS© Statistics version 21 using multiple logistic regression model, Chi-square, independent-sample t-test, and Fisher’s exact test. A p value of ≤0.05 was considered significant. Results: Klebsiella pneumoniae was the most frequently (89.8%) isolated organism. Chest (22%) and urinary tract infections (22%) were the main sources of CRE infections. Combined therapy resulted in significantly more deaths than the monotherapy (p=0.005). By logistic regression, the significant predictors were septic shock (Odds ratio=8.82), Charlson Comorbidity index (CCI) of two (Odds ratio=2.39) and renal impairment (Odds ratio=4.4). About 66% of patients for whom the antibiotics were initiated after >24 h (65.2%), died (Chi-square =1.55, p=0.22). Conclusions: This study showed high mortality in infected patients with CRE infections and that the drug monotherapy and combination therapies were not effective in reducing patient mortality. Knowledge on risk factors associated with CRE infections could be useful for designing future treatment regimens to combat such infections and reduce mortality.References
Ting S. W., Lee C. H., Liu J. W. Risk factors and outcomes for the acquisition of carbapenem-resistant
Gram-negative bacillus bacteremia: a retrospective propensity-matched case control study. J. Microbiol.
Immunol. Infect. 2018; 51 (5): 621-8. DOI: 10.1016/j.jmii.2016.08.022, PMid: 28732563
Kohanski M. A., Dwyer D. J., Collins J. J. How antibiotics kill bacteria: from targets to networks. Nat. Rev.
Microbiol. 2010; 8 (6): 423-435. DOI: 10.1038/nrmicro2333, PMid: 20440275, PMCid: PMC2896384
Tamma P. D., Simner P. J. Phenotypic detection of carbapenemase-producing organisms from clinical
isolates. J. Clin. Microbiol. 2018; 56 (11):e01140. DOI: 10.1128/JCM.01140-18, PMid: 30158194, PMCid:
PMC6204673
Alotaibi F. Carbapenem-Resistant Enterobacteriaceae: An update narrative review from Saudi Arabia. J
Infect Public Health. 2019, 12(4): S1876-0341(19)30134-0.
Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience
with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect, 2012; 18 (5): 439-48. DOI:
1111/j.1469-0691.2012.03823.x, PMid: 22507111
Garbati M.A. Sakkijha H., Abushaheen A. Infections due to carbapenem resistant Enterobacteriaceae
among Saudi Arabian hospitalized patients: a matched case-control study. Bio Med Res Int, 2016;
: 1-9. DOI: 10.1155/2016/3961684, PMid: 27144165, PMCid:PMC4837245
Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella
pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp
Epidemiol, 2008; 29 (12): 1099-1106. DOI: 10.1086/592412, PMid: 18973455
de Oliveira MS, de Assis DB, Freire MP, et al. Treatment of KPC-producing Enterobacteriaceae:
suboptimal efficacy of polymyxins. Clin Microbiol Infect, 2015; 1(2): 179.e1-7. DOI:
1016/j.cmi.2014.07.010, PMid: 25599940
Ben-David D, Kordevani R, Keller N, et al. Outcome of carbapenem resistant Klebsiella pneumoniae
bloodstream infections. Clin Microbiol Infect. 2012; 18(1):54-60. doi: 10.1111/j.1469-0691.2011.03478.x,
PMid: 21722257
Morrill HJ., Pogue JM., Kaye KS., LaPlante KL. Treatment Options for Carbapenem-Resistant
Enterobacteriaceae Infections. Open Forum Infect Dis. 2015 Apr; 2(2): ofv050. DOI: 10.1093/ofid/ofv050,
PMid: 26125030, PMCid: PMC4462593
Sheu CC, Chang YT, Lin SY, Chen YH, Hsueh PR. Infections Caused by Carbapenem-Resistant
Enterobacteriaceae: An Update on Therapeutic Options. Front Microbiol. 2019 Jan 30; 10:80. DOI:
3389/fmicb.2019.00080, PMid: 30761114, PMCid: PMC6363665
Thaden JT, Lewis SS, Hazen KC, et al. Rising rates of carbapenem-resistant enterobacteriaceae in
community hospitals: a mixed-methods review of epidemiology and microbiology practices in a network of
community hospitals in the southeastern United States. Infect Control Hosp Epidemiol, 2014; 35 (8): 978- 983. DOI: 10.1086/677157, PMid: 25026612m PMCid: PMC4217156
Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella
pneumoniae carbapenemases. Lancet Infect Dis, 2013; 13 (9): 785-796. DOI: 10.1016/S1473- 3099(13)70190-7
Kontopidou F, Giamarellou P, Katerelos A, et al. Infections caused by carbapenem-resistant Klebsiella
pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and
therapeutic options. Clin Microbiol Infect, 2014; 20 (2): O117-123. DOI: 10.1111/1469-0691.12341, PMid:
Souli M, Galani I, Antoniadou A, et al. An outbreak of infection due to β-lactamase Klebsiella pneumoniae
carbapenemase 2–producing K. pneumoniae in a Greek university hospital: molecular characterization,
epidemiology, and outcomes. Clin Infect Dis, 2010; 50 (3): 364-733. DOI: 10.1086/649865, PMid:
Marchaim D, Chopra T, Perez F, et al. Outcomes and genetic relatedness of carbapenem-resistant
enterobacteriaceae at Detroit medical center. Infect Control Hosp Epidemiol, 2011; 32 (9): 861-871. DOI:
1086/661597, PMid: 21828966, PMCid: PMC4067763
Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenemresistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect, 2013;
(1): E23-30. DOI: 10.1111/1469-0691.12070, PMid: 23137235
Sader HS, Castanheira M, Flamm RK, et al. Tigecycline activity tested against carbapenem-resistant
Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010–
. Diagn Microbiol Infect Dis, 2015; 83 (2): 183-186. DOI: 10.1016/j.diagmicrobio.2015.06.011,
PMid: 26164275
Buehrle DJ, Shields RK, Clarke LG, et al. Carbapenem-resistant Pseudomonas aeruginosa bacteremia: risk
factors for mortality and microbiologic treatment failure. Antimicrob Agents Chemother, 2017; 61 (1):
e01243-16. DOI: 10.1128/AAC.01243-16, PMid: 27821456, PMCid: PMC5192105
de Maio Carrilho CM, de Oliveira LM, Gaudereto J, et al. A prospective study of treatment of carbapenemresistant Enterobacteriaceae infections and risk factors associated with outcome. BMC Infect Dis, 2016; 16
(10: 629. DOI: 10.1186/s12879-016-1979-z, PMid: 27809803, PMCid: PMC5096338
Schwartz-Neiderman A, Braun T, Fallach N, et al. Risk factors for carbapenemase-producing carbapenemresistant enterobacteriaceae (CP-CRE) acquisition among contacts of newly diagnosed CP-CRE patients.
Infect Control Hosp Epidemiol, 2016; 37 (10): 1219-25. DOI: 10.1017/ice.2016.153, PMid: 27452597
Crespo MP, Woodford N, Sinclair A, et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa
producing VIM-8, a novel metallo-β-lactamase, in a tertiary care center in Cali, Colombia. J Clin
Microbiol, 2004; 42 (11): 5094-5101. DOI: 10.1128/JCM.42.11.5094-5101.2004, PMid: 15528701,
PMCid: PMC525211
Kotsanas D, Wijesooriya WR, Korman TM, et al. “Down the drain”: carbapenem-resistant bacteria in
intensive care unit patients and handwashing sinks. Med J Aust, 2013; 198 (5): 267-269. DOI:
5694/mja12.11757, PMid: 23496403
Perez F, Endimiani A, Ray AJ, et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella
pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob
Chemother, 2010; 65 (8): 1807-18. DOI: 10.1093/jac/dkq191, PMid: 20513702, PMCid: PMC2904665
Downloads
Published
Issue
Section
License
Copyright (c) 2020 knowledge kingdom publishing
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
